Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin as Monotherapy and in Combination With Anti-Cancer Treatments in RRMM (DREAMM 5)
NCT04126200Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Oct 2019
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of belantamab mafodotin in multiple myeloma (MM) (15 arms), sponsored by GSK. Primary endpoint: Number of Participants Randomized Across Sub-studies at Day 1. Started Oct 2019; status: active, not recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04126200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126200.